Vascular Biogenics Ltd. (NASDAQ:VBLT) – Roth Capital boosted their FY2016 earnings estimates for shares of Vascular Biogenics in a research report issued to clients and investors on Thursday. Roth Capital analyst J. Pantginis now forecasts that the firm will post earnings per share of ($0.58) for the year, up from their previous forecast of ($0.64). Roth Capital currently has a “Buy” rating and a $17.00 target price on the stock. Roth Capital also issued estimates for Vascular Biogenics’ Q4 2016 earnings at ($0.16) EPS, FY2017 earnings at ($0.63) EPS and FY2018 earnings at ($0.67) EPS.

Separately, Zacks Investment Research lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Wednesday, October 19th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $10.90.

Vascular Biogenics (NASDAQ:VBLT) opened at 4.80 on Monday. The firm’s market cap is $113.29 million. The firm’s 50-day moving average is $5.05 and its 200 day moving average is $4.30. Vascular Biogenics has a 12-month low of $2.76 and a 12-month high of $7.58.

Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings results on Thursday, November 10th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03.

Several hedge funds and other institutional investors have recently made changes to their positions in VBLT. Franklin Resources Inc. bought a new position in shares of Vascular Biogenics during the second quarter valued at $4,191,000. First Eagle Investment Management LLC raised its position in shares of Vascular Biogenics by 371.1% in the second quarter. First Eagle Investment Management LLC now owns 923,239 shares of the biopharmaceutical company’s stock valued at $4,256,000 after buying an additional 727,273 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Vascular Biogenics during the second quarter valued at $1,844,000. Macquarie Group Ltd. bought a new position in shares of Vascular Biogenics during the second quarter valued at $1,521,000. Finally, Turner Investments L.P. bought a new position in shares of Vascular Biogenics during the second quarter valued at $1,007,000. Institutional investors and hedge funds own 14.42% of the company’s stock.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

5 Day Chart for NASDAQ:VBLT

Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.